Hard and soft tissue healing around implants with Ag coating: An experimental study in dogs.

Introduction The purpose of this randomized controlled canine experimental study was to evaluate peri­implant hard and soft tissue healing around implants with silver coating. Methods All mandibular premolars and molars of five male beagle dogs were extracted. 25 test and 25 control implants were randomly installed and connected with the healing abutments. After 2 and 4 month healing period, implants with soft and hard tissues were obtained for histologic and histomorphometric analysis. Results In mesio-distal sections, supracrestal tissue attachment dimensions were 4.03±0.48 mm and 4.25±0.66 mm for test and 4.34±0.6 mm and 5.21±0.72 mm for control implants at 2 and 4 month healing time. The respective crestal bone loss values were 1.10±0.69 mm and 0.74±0.67 mm for test and 1.13±0.48 mm and 1.49±0.65 mm for control implants. The differences were statistically significant only in the 4-month healing period. In buccolingual sections, supracrestal tissue attachment height at 2 and 4 month healing periods were 4.09±0.64 mm and 4.5±0.8 mm for test implants and 4.17±0.76 mm and 4.48±0.76 mm for control implants. The respective mean values for crestal bone loss were 1.31±0.6 mm and 1.02±0.58 mm for test implants, and 1.28±0.61 mm and 1.29±0.69 mm for control implants. No statistical significant differences were recorded, apart from the height of connective tissue at the 2 month healing group. No significant difference in terms of BIC between implants or healing periods was recorded. Conclusions The Ag implant coating resulted in smaller supracrestal tissue attachment dimensions and less bone loss. Within the limits of a canine study, prevention of crestal bone loss along with the effectiveness of Ag antimicrobial properties in dental implantology is demonstrated.

Expression of cannabinoid and cannabinoid-related receptors in the oral mucosa of healthy cats and cats with chronic gingivostomatitis.

OBJECTIVES: Feline chronic gingivostomatitis (FCGS) is an oral disease. Cats with FCGS experience intense oral pain. Some cats remain refractory to current therapies based on dental extraction and adjuvant medical treatment; it is therefore necessary to investigate alternative therapeutic targets involved in inflammatory mechanisms and pain, namely the endocannabinoid system (ECS). The present study investigated the expression of cannabinoid receptors type 1 (CB1R) and 2 (CB2R), and cannabinoid-related receptors G protein-coupled receptor 55 (GPR55), transient receptor potential ankyrin 1 (TRPA1) and serotonin 1a receptor (5-HT1aR), in the oral mucosa of healthy cats to determine whether there was altered expression and distribution in cats with FCGS. METHODS: Samples of caudal oral mucosa were collected from eight control cats (CTRL cats) and from eight cats with FCGS (FCGS cats). Tissue samples were processed using an immunofluorescence assay with cat-specific antibodies, and the immunolabelling of the receptors studied was semiquantitatively evaluated. RESULTS: The mucosal epithelium of the CTRL cats showed CB1R, TRPA1 and 5-HT1aR immunoreactivity (IR), while CB2R and GPR55 IR were generally not expressed. In the CTRL cats, the subepithelial inflammatory cells expressed CB2R, GPR55 and 5-HT1aR IR. In the FCGS cats, all the receptors studied were markedly upregulated in the epithelium and inflammatory infiltrate. CONCLUSIONS AND RELEVANCE: Cannabinoid and cannabinoid-related receptors are widely expressed in the oral mucosa of healthy cats and are upregulated during the course of FCGS. The presence of cannabinoid and cannabinoid-related receptors in healthy tissues suggests the possible role of the ECS in the homeostasis of the feline oral mucosa, while their overexpression in the inflamed tissues of FCGS cats suggests the involvement of the ECS in the pathogenesis of this disease, with a possible role in the related inflammation and pain. Based on the present findings, ECS could be considered a potential therapeutic target for patients with FCGS.

Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease.

Objectives The objective of this study was to evaluate the analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. Methods Six adult client-owned cats with chronic gingivostomatitis (weighing 5.1 ± 1.1 kg) were recruited for a randomised, prospective, blinded, saline-controlled, crossover study. Pain scores, dental examination, stomatitis score and buccal pH measurement were conducted on day 1 under sedation in all cats. On day 2, animals were randomised into two groups and administered one of the two treatments buccally (group A received buprenorphine 0.02 mg/kg and group B received 0.9% saline) and vice versa on day 3. Pain scores and food consumption were measured at 30, 90 and 360 mins after the administration of buprenorphine. Blood samples were taken at the same time and plasma buprenorphine concentration was measured by liquid chromatography-mass spectrometry. Data were statistically analysed as non-parametric and the level of significance was set as P <0.05. Results There were no major side effects after buprenorphine administration. Buccal pH values ranged between 8.5 and 9.1 and the stomatitis disease activity index between 10 and 22 (17.8 ± 4.5), with the scale ranging from 0-30. The maximum buprenorphine plasma concentration (14.8 ng/ml) was observed 30 mins after administration and there was low inter-individual variability. There was a significant difference between baseline pain scores compared with pain scores after buprenorphine ( P <0.05), and between the saline and buprenorphine group at 30 mins ( P = 0.04) and 90 mins ( P = 0.04). There was also a significant effect of the stomatitis index on the pain score. Regarding the pharmacokinetic parameters, cats with stomatitis showed lower bioavailability and shorter absorption half-life after buccal administration of buprenorphine compared with normal cats in previous studies. Conclusions and relevance Buccal administration of buprenorphine in cats with gingivostomatitis produces an analgesic effect and low inter-individual variability in plasma concentration, and it can be incorporated in their multimodal analgesia plan.